Literature DB >> 19301061

Tuberculosis after anti-TNF therapy.

Omer Nuri Pamuk, Salim Dönmez.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19301061     DOI： 10.1007/s10067-009-1159-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  4 in total

1.  Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension.

Authors:  Elena Bargagli; Mauro Galeazzi; Francesca Bellisai; Luca Volterrani; Paola Rottoli
Journal:  Respiration       Date:  2005-12-09       Impact factor: 3.580

2.  Increased risk of tuberculosis in patients treated with antitumor necrosis factor alpha.

Authors:  Osman Elbek; Meral Uyar; Neriman Aydin; Sermin Börekçi; Nazan Bayram; Hasan Bayram; Oner Dikensoy
Journal:  Clin Rheumatol       Date:  2008-12-04       Impact factor: 2.980

3.  An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis.

Authors:  C P Denton; M Engelhart; N Tvede; H Wilson; K Khan; X Shiwen; P E Carreira; F Diaz Gonzalez; C M Black; F H van den Hoogen
Journal:  Ann Rheum Dis       Date:  2008-09-09       Impact factor: 19.103

4.  A low prevalance of purified protein derivative test positivity in Turkish patients with rheumatoid arthritis. Association with clinical features and HRCT findings.

Authors:  I H Köker; O N Pamuk; C Karlikaya; N Tunçbilek; N Cakir
Journal:  Clin Exp Rheumatol       Date:  2007 Jan-Feb       Impact factor: 4.473
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.